Publication
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerAnaplastic Large Cell Lymphomacivic_curation1.00
- cancerInflammatory Myofibroblastic Tumorcivic_curation1.00
- cancerNeuroblastomacivic_curation1.00
- drugCrizotinibcivic_curation1.00
- geneALKcivic_curation1.00
- variantALK F1174Lcivic_curation1.00
- variantALK F1245Ccivic_curation1.00
- variantALK Fusioncivic_curation1.00
- variantALK Fusioncivic_curation1.00
- variantALK R1275Qcivic_curation1.00
Curated evidence
Evidence citing this paper (6)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23598171
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ALK Fusion1 | ||||||||
| Crizotinib | Anaplastic Large Cell Lymphoma | Predictive | B | Supports Sensitivity Response | 4 | accepted | EID1241In the second part of this Phase I study NCT00939770, nine patients between the ages of 12 months and 22 years with anaplastic large cell lymphoma (ALCL), who were refractory to treatment and for whom… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC | civic |
| ALK Fusion1 | ||||||||
| Crizotinib | Inflammatory Myofibroblastic Tumor | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID1243As part of a phase 1 dose-escalation trial (NCT00939770), seven patients between ages 12 months and 22 years with relapsed or refractory inflammatory myofibroblastic tumors with ALK-rearrangement were… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC | civic |
| ALK F1174L1 | ||||||||
| Crizotinib | Neuroblastoma | Predictive | C | Does Not Support Sensitivity Response | 3 | accepted | EID1271In a Phase I trial (NCT00939770) of the drug crizotinib in pediatric patients, a subset of 11 neuroblastoma patients were characterized for mutations in ALK. Of these 11 patients, 4 had the F1174L mut… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC | civic |
| ALK F1245C1 | ||||||||
| Crizotinib | Neuroblastoma | Predictive | C | Supports Resistance | 3 | accepted | EID1333A participant in Children's Oncology Group (COG) study AVDL0912 with measurable neuroblastoma mutated at ALK F1245C was administered crizotinib at 100mg twice daily. The patient showed progressive di… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC | civic |
| ALK R1275Q2 | ||||||||
| Crizotinib | Neuroblastoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1269This Phase I study of crizotinib involved a cohort of pediatric neuroblastoma patients between ages 12 months and 22 years. In 11 patients with characterized ALK mutations, 4 had R1275Q mutations, and… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC | civic |
| 〃 | Neuroblastoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1270A cohort of pediatric neuroblastoma patients ages 12 months to 22 years were assessed for response to crizotinib in a Phase I study. 11 patients in this cohort had characterized ALK mutations, 4 of w… (full text at CIViC) PMID 23598171 · Mossé et al., 2013 · Open in CIViC | civic |